Τόμος 33 (2015) – Τεύχος 3 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 33 (2015) – Issue 3 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Παναγιώτης Τζιτζής, Νικόλαος Στάικογλου, Πέτρος Παπαλέξης, Χρυσοβαλάντης Τσάντσας, Μαρία Μυρωνίδου-Τζουβελέκη

Α’ Εργαστήριο Φαρμακολογίας, Σχολή Επιστημών Υγείας, Ιατρικό Τμήμα, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ) ,Θεσσαλονίκη, Ελλάς

Panagiotis Tzitzis, Nikolaos Staikoglou, Petros Papalexis, Chrysovalantis Tsantsas, Maria Mironidou-Tzouveleki

A’ Laboratory of Pharmacology, Faculty of Health Sciences, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

2. Linnaeus C.: Species Plantarum 2: 1027. Salvius, Stockholm, 1973 [Facsimile edition, 1957–1959. Ray Society, London, U.K.]

3. Company, Houghton Mifflin; American Heritage Dictionaries (2007-11-14). Spanish Word Histories and Mysteries. Houghton Mifflin Harcourt. p. 142.ISBN 0618910549

4. Greydanus D., Holt M.: Cannabis: a controversial 21st-century drug of antiquity. Georgian Med. News (230): 24-30 (2014)

5. Κέντρο Ελληνικής Γλώσσας. Ηροδότου Ιστορίαι, Μελπομένη. 4.75.1: [4.74.1] Κι έχουν ένα καννάβι που φυτρώνει στη γη τους, ολόιδιο με το λινάρι, μονάχα στο πάχος και στο μάκρος διαφέρουν· σ᾽ αυτά το καννάβι είναι πολύ μεγαλύτερο. Ετούτο βλασταίνει από τη γη, και από μόνο του και με σπορά, κι οι Θράκες απ᾽ τη μεριά τους κάνουν απ᾽ αυτό πανωφόρια σ᾽ όλα τα πάντα ολόιδια με τα λινά. http://www.greek-language.gr/Resources/ancient_greek/library/browse.html?text_id=30&page=107

6. Godley A.D.: Cambridge 1920,4.75.1-2: «Ταύτης ὦν οἱ Σκύθαι τῆς καννάβιος τὸ σπέρμα ἐπεὰν λάβωσι, ὑποδύνουσι ὑπὸ τοὺς πίλους, καὶ ἔπειτα ἐπιβάλλουσι τὸ σπέρμα ἐπὶ τοὺς διαφανέας λίθους τῷ πυρί• τὸ δὲ θυμιᾶται ἐπιβαλλόμενον καὶ ἀτμίδα παρέχεται τοσαύτην ὥστε Ἑλληνικὴ οὐδεμία ἄν μιν πυρίη ἀποκρατήσειε. Οἱ δὲ Σκύθαι ἀγάμενοι τῇ πυρίῃ ὠρύονται. τοῦτό σφι ἀντὶ λουτροῦ ἐστι. οὐ γὰρ δὴ λούονται ὕδατι τὸ παράπαν τὸ σῶμα.»

7. Μυρωνίδου-Τζουβελέκη Μ. και συν.: Φυτά: μαγεία, θρησκεία ή μόνο ψευδαισθήσεις; University Studio Press, Θεσ/νικη, pp. 13-36, 2010

8. Dana Larsen (Ed.): Is the world’s most famous sailorman tooting more than just spinach in his pipe? Cannabis Culture Magazine. Febr. 2005. [Internet] [Oct. 2014]. http://www.cannabisculture.com/articles/3568.html

9. Jaffe J., Peterson R., Hodgson R. (Eds): Αdictions-Issues and answers,Harper and Raw. Open University Press. New York 1981. ISBN: 9780335098026. p. 81.

10. Braude M., Szara S. (Eds): Pharmacology of Marihuana, Α Monograph of the National Institute on Drug Abuse. Raven Press, New York, 1976

11. Advisory on Drug Dependence Report: Cannabis ή Wootton Report (1968)

12. DuPont R.: Marihuana: An Issue Comes of Age. In: Braude and Szara (Eds). Pharmacology of Marihuana. Vol. 1, pp. 3-8, Raven Press, New York, 1976

13. Commission on Inquiry into Non-Medical Use of Drugs: Interim Report or LeDain Report, 1970

14. Grinspoon L. (Ed.): Marihuana Reconsidered. Harvard University Press, p. 3, 1971

15. Brotman R., Suffet F. (Eds): Marihuana Users’ Views of Marihuana Use. In: Zubin, J. and Freedman, A.: The Psychology of Adolescence. Grime and Stratton New York, 1970

16. Department of Health: Marijuana and Health. First Annual Report to the US. Congress 1971

17. National Commission on Marihuana and Drug Abuse (NDMDA) Marihuana, A Signal of Misunderstanding (1972) & NDMDA: Drug Abuse in America: Problem in Perspective,1973

18. Mikuriya T.H.: Marijuana: Medical Papers 1839-1972. MediComp Press, Oakland, California, 1973

19. Brecher E. (Ed.): Licit and Illicit Drugs. Little Brown & Co. ISBN: 0316107174. 1973

20. Rubin S., Commitas L.: Canja in Jamaica. The Hague: Mouton, 1975

21. Carter W.E. (Ed.): Cannabis in Costa Rica: A Study of Chronic Marijuana Use, Philadelphia: Institute for Study of Human Issues, 1980

22. Satz P., Fletcher J., Sutker L. (Eds): Neurophysiologic, intellectual and personality correlates of chronic marihuana use in native Costa Ricans. New York Academy of Sciences: Chronic Cannabis Use, 1977

23. Stefanis C., Boulougouris J., Liakos A. (Eds): Hashish: Studies of Long Term Use. New York: Raven Press, 1977

24. Martin A. Lee (Ed.): Truth drugs. The CIA has long been searching for the ultimate way of making you talk. Cannabis Culture Magazine. Nov. 2002. [Internet] [Oct. 2014]. http://www.cannabisculture.com/articles/2603.html

25. United Nations Office on Drugs and Crime: Word drug report 2014. Cannabis. http://www.unodc.org/wdr2014/en/cannabis.html

26. United States, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, “Monitoring the Future Surveys”.

27. Health Canada, 2012 Canadian Alcohol and Drug Use Monitoring Survey (Ottawa, 2013)

28. Ερευνητικό Πανεπιστημιακό Ινστιτούτο Ψυχικής Υγιεινής. Πανελλήνια έρευνα στο σχολικό πληθυσμό για τη χρήση εξαρτησιογόνων ουσιών (Έρευνα ESPAD)[Internet] [Oct. 2014].Available from: http://www.epipsi.gr/Tekmiriosi/epid/Epidimiologikes_erevnes/espadgr.php

29. Canavaccio: Κείμενα περί της ηδονιστικής δρόγης / Συλλογικό έργο: Κώστας Γκοτσίνας, Λίνα Καρανασοπούλου, Βασίλης Καρύδης, Κυριάκος Κάσσης, Θωμάς Κοροβίνης, Φώτης Παπαδόπουλος, Γιώργος Χριστοδουλόπουλος, Βαγγέλης Ψαραδάκης. μετάφραση Θεοδόσης Βολκώφ, Αγάπη Νταϊφά, Αρίσταρχος Παπαδημητρίου. – 1^η έκδ. – Αθήνα : Heteron, 2008.

30. European Monitoring for Drugs and drugs addiction. Center for Legal topic overviews: possession of cannabis for personal use [Internet] [Oct. 2014]. Available from: http://www.emcdda.europa.eu/legal-topic-overviews/cannabis-possession-for-personal-use

31. United Nations. Single Convention on Narcotic drugs, 1961. [Internet] [Oct. 2014]. Available from: https://www.unodc.org/pdf/convention_1961_en.pdf

32. Wade D., Robson P., House H., Makela P., Aram J.: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17(1): 21-29 (2003)

33. GW Pharmaceuticals. Sativex Oromucosal Spray. Prescriber Information. [Internet] [Jan. 2015]. Available from: http://www.gwpharm.com/prescriberinformation.aspx

34. National Conference of State Legislatures. State Medical Marijuana law. Published in Nov, 13 2014 [Internet] [Dec. 2014]. Available from: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx

35. Maas A.I., Murray G., Henney H., Kassem N., Legrand V., Mangelus M., et al.: Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 5(1): 38-45 (2006)

36. Burstein S.H., Karst M., Schneider U., Zurier R.B.: Ajulemic acid: A novel cannabinoid produces analgesia without a high. Life Sci. 75(12): 1513-1522 (2004)

37. Dyson A., Peacock M., Chen A., Courade J.P., Yaqoob M., Groarke A., et al.: Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116(1-2): 129-137 (2005)

38. Gratzke C., Streng T., Stief C.G., Alroy .I, Limberg B.J., Downs T.R., et al.: Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction. J. Urol. 185(2): 731-736 (2011)

39. Cahill K., Stevens S., Perera R., Lancaster T.: Pharmacological interventions for smoking cessation: an over-view and network meta-analysis. Cochrane Database Syst. Rev. 31;5: 2013 CD009329.

40. Suicide risk fears over diet pill: BBC News. 15 June 2007. [Internet] http://news.bbc.co.uk/2/hi/health/6755665.stm

41. Freund T.F., Katona I., Piomelli D.: Role of endogenous cannabinoids in synaptic signalling. Physiol. Rev. 83: 1017-1066 (2003)

42. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G.: Classification of cannabinoid receptors. Pharmacol. Rev. 54: 161-202 (2002)

43. Alexander S.P., Kendall D.A.: The complications of promiscuity: endocannabinoid action and metabolism. Br. J. Pharmacol. 152: 602-623 (2007)

44. Basavarajappa B.S.: Critical enzymes involved in endocannabinoid metabolism. Protein Pept. Lett. 14: 237-246 (2007)

45. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C.: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11: 563-583 (1991)

46. Jansen E.M., Haycock D.A., Ward S.J., Seybold V.S.: Distribution of cannabinoid receptors in rat brain deter-mined with aminoalkylindoles. Brain Res. 575: 93-102 (1992)

47. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564 (1990)

48. Munro S., Thomas K.L., Abu-Shaar M.: Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65 (1993)

49. Kotsikorou E., Sharir H., Shore D.M., Hurst D.P., Lynch D.L., Madrigal K.E., et al.: Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 52: 9456-9469 (2013)

50. McHugh D., Roskowski D., Xie S., Bradshaw H.B.: Δ(9)-THC and N-arachidonoyl glycine regulate BV-2 microglial morphology and cytokine release plasticity: implications for signaling at GPR18. Front. Pharmacol. 4: 162 (2014)

51. Passos I., Mironidou-Tzouveleki M.: Cannabinoids: Therapeutic potential against cocaine dependence. Epitheorese Klinikes Farmakologias kai Farmakokinetikes. 29(1): 7-14 (2011)

52. Pisanti S., Malfitano A.M., Grimaldi C., Santoro A., Gazzerro P., Laezza C., et al.: Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract. Res. Clin. Endocrinol. Metab. 23(1): 117-131 (2009)

53. Bowles D.W., O’ Bryant C.L., Camidge D.R., Jimeno A.: The intersection between cannabis and cancer in the United States. Crit. Rev. Oncol. Hematol. 83(1): 1-10 (2012)

54. Todaro B.: Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J. Natl. Comp. Canc. Netw. 10(4): 487-492 (2012)

55. Cridge B.J., Rosengren R.J.: Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Management Res. 5: 301-313 (2013)

56. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., et al.: Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214(1): 173-180 (1993)

57. Blázquez C., Carracedo A., Barrado L., Real P.J., Fernández-Luna J.L., Velasco G., et al.: Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20(14): 2633-2635 (2006)

58. Wang D., Wang H., Ning W., Backlund M.G., Dey S.K., DuBois R.N.: Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res. 68(15): 6468-6476 (2008)

59. Xu X1., Liu Y., Huang S., Liu G., Xie C., Zhou J., et al.: Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet. Cytogenet. 171(1): 31-38 (2006)

60. Velasco G., Sánchez C., Guzmán M.: Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer 12(6): 436-444 (2012)

61. Shrivastava A., Kuzontkoski P.M., Groopman J.E., Prasad A.: Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol. Cancer Ther. 10(7): 1161-1172 (2011)

62. Hermanson D., Marnett L.: Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev. 30(3-4): 599-612 (2011)

63. Fleming A., Noda T., Yoshimori T., Rubinsztein D.C.: Chemical modulators of autophagy as biological probes and potential therapeutics. Nat. Chem. Biol. 7: 9-17 (2011)

64. Danbo I., Donadelli M., Costanzo C., Dalla E. Pozza, D’Alessandro A, Zolla L., Palmieri M.: Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Disease 4: e664; (2013) doi:10.1038/cddis.2013.151

65. Lozano-Ondoua A.N., Hanlon K.E., Symons-Liguori A.M., Largent-Milnes T.M., Havelin J.J., Ferland H.L. et al.: Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J. Bone Miner. Res. 28(1): 92-107 (2013)

66. Grotenhermen F., Müller-Vahl K.: The therapeutic potential of cannabis and cannabinoids. Dtsch. Arztebl. Int. 109(29-30): 495-501 (2012)

67. Struwe M., Kaempfer S.H., Geiger C.J., Pavia A.T., Plasse T.F., Shepard K.V., et al.: Effect of dronabinol on nutritional status in HIV infection. Ann. Pharmacother. 27: 827-831 (1993)

68. Haney M., Gunderson E.W., Rabkin J., Hart C.L., Vosburg S.K., Comer S.D., et al.: Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J. Acquir. Immune. Defic. Syndr. 45: 545–54 (2007)

69. Jatoi A., Windschitl H.E., Loprinzi C.L., Sloan J.A., Dakhil S.R., Mailliard J.A., et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol. 20: 567-573 (2002)

70. Volicer L., Stelly M., Morris J., McLaughlin J., Volicer B.J.: Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry 12: 913-919 (1997)

71. Svendsen K.B., Jensen T.S., Bach F.W.: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329: 253 (2004)

72. Karst M., Salim K., Burstein S., Conrad I., Hoy L., Schneider U.: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290: 1757-1756 (2003)

73. Raft D., Gregg J., Ghia J., Harris L.: Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: psychological correlates of the analgesic response. Clin. Pharmacol. Ther. 21: 26-33 (1977)

74. Ostenfeld T., Price J., Albanese M., Bullman J., Guillard F., Meyer I., Leeson R., et al.: A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin. J. Pain 27: 668-676 (2011)

75. Walker J.M., Huang S.M., Strangman N.M., Tsou K., Sanudo-Pena M.C.: Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA 96: 12198-12203 (1999)

76. Riedel G., Fadda P., McKillop-Smith S., Pertwee R.G., Platt B., Robinson L.: Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br. J. Pharmacol. 156(7): 1154-1166 (2009)

77. Sallan S.E., Zinberg N.E., Frei E.: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293(16): 795-797 (1975)

78. Frytak S, Moertel CG, O’Fallon JR, Rubin J, Creagan ET, O’Connell M.J., et al.: Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann. Int. Med. 91(6): 825-830 (1979)

79. Dalzell A.M., Bartlett H., Lilleyman J.S.: Nabilone: an alternative antiemetic for cancer chemotherapy. Arch. Dis, Child. 61(5): 502-505 (1986)

80. Lucas V.S.,Jr., Laszlo J.: Delta 9-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 243(12): 1241-1243 (1980)

81. Bowles D.W., O’Bryant C.L., Camidge D.R., Jimeno A.: The intersection between cannabis and cancer in the United States. Crit. Rev. Oncol./Hematol. 83(1): 1-10 (2012)

82. Rock E.M., Sticht M.A., Duncan M., Stott C., Parker L.A.: Evaluation of the potential of the phytocannabinoids, can­nabidivarin (CBDV) and Delta(9)-tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br. J. Pharmacol. 170(3): 671-678 (2013)

83. Bolognini D., Rock E.M., Cluny N.L., Cascio M.G., Limebeer C.L., Duncan M., et al.: Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br. J. Pharmacol. 168(6): 1456-1470 (2013)

84. Rock E.M., Kopstick R.L., Limebeer C.L., Parker L.A.: Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br. J. Pharmacol. 170(3): 641-648 (2013)

85. Ben Amar M.: Cannabinoids in medicine: A review of their therapeutic potential. J. Ethnopharmacol. 105(1-2): 1-25 (2006)

86. Abrams D.I., Jay C.A., Shade S.B., Vizoso H., Reda H., Press S., et al.: Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68(7): 515-21 (2007)

87. Ware M.A., Wang T., Shapiro S., Robinson A., Ducruet T., Huynh T., et al.: Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 182(14): 694-701 (2010)

88. Johnson J.R., Burnell-Nugent M., Lossignol D., Ganae-Motan E.D., Potts R., Fallon M.T.: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom. Manage 39(2): 167-179 (2010)

89. Lynch M.E., Campbell F.: Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br. J. Clin Pharmacol. (5): 735-44 (2011)

90. Malec J., Harvey R.F., Cayner J.J.: Cannabis effect on spasticity in spinal cord injury. Arch. Phys. Med. Rehabil. 63(3): 116-118 (1982)

91. van den Elsen G.A., Ahmed A.I., Lammers M., Kramers C., Verkes R.J., van der Marck M.A., et al.: Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res. Rev. 14: 56-64 (2014)

92. Gloss D., Vickrey B.: Cannabinoids for epilepsy. Cochrane Database Syst Rev. 5: 3 (2014) CD009270.

93. Dos Santos R.G., Hallak J.E., Leite J.P., Zuardi A.W., Crippa J.A.: Phytocannabinoids and epilepsy. J. Clin. Pharm. Ther. 40(2): 135-143 (2015)

94. González-Naranjo P., Campillo N.E., Pérez C., Páez J.A.: Multitarget cannabinoids as novel strategy for Alzheimer disease. Curr. Alzheimer Res. 10(3): 229-239 (2013)

95. Müller-Vahl K.R.: Treatment of Tourette syndrome with cannabinoids. Behav. Neurol. 27(1): 119-124 (2013)

96. Müller-Vahl K.R., Schneider U., Koblenz A., Jöbges M., Kolbe H., Daldrup T., et al.: Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35(2): 57-61 (2002)

97. Müller-Vahl K.R., Schneider U., Prevedel H., Theloe K., Kolbe H., Daldrup T., et al.: Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry 64(4): 459-465 (2003)

98. Petro D.J.: Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 21(1): 81, 85 (1980)

99. Wade D.T., Collin C., Stott C., Duncombe P.: Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler. 16(6): 707-714 (2010)

100. Serpell M.G., Notcutt W., Collin C.: Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 260(1): 285-295 (2013)

101. García C., Palomo-Garo C., García-Arencibia M., Ramos J., Pertwee R., Fernández-Ruiz J.: Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease. Br. J. Pharmacol. 163(7): 1495-1506 (2011)

102. Campbell V.A., Gowran A.: Alzheimer’s disease; taking the edge off with cannabinoids? Br. J. Pharmacol. 152(5): 655-662 (2007)

103. Eubanks L.M., Rogers C.J., Beuscher A.E., Koob G.F., Olson A.J., Dickerson T.J., et al.: A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol. Pharm. 3(6): 773-777 (2006)

104. Ramírez B.G., Blázquez C., Gómez del Pulgar T., Guzmán M., de Ceballos M.L.: Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25(8): 1904-1913 (2005)

105. Aso E., Ferrer I.: Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front. Pharmacol. 5: 37 (2014)

106. Casarejos M.J., Perucho J., Gomez A., Muñoz M.P., Fernandez-Estevez M., Sagredo O., et al.: Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J. Alzheimers Dis. 35(3): 525-539 (2013)

107. Baker D., Pryce G., Giovannoni G., Thompson A.J.: The therapeutic potential of cannabis. Lancet Neurol. 2(5): 291-298 (2003)

108. Papathanasopoulos P., Messinis L., Lyros E., Kastellakis A., Panagis G.: Multiple sclerosis, cannabinoids, and cognition. J. Neuropsychiatry Clin. Neurosci. 20(1): 36-51 (2008)